Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trialGavin Brittain, John A. Snowden, Kate E. M. Duffy et al.|BMJ Open|2024Cited by 10